Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 10, 2017BloodOpen Access

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

RMReid W. MerrymanHarvard UniversityHKHaesook T. KimDana-Farber Cancer Institute
Pier Luigi Zinzani
Pier Luigi ZinzaniUniversité Claude Bernard Lyon 1

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Merryman et al. (2017) studied this question.

synapsesocial.com/papers/6a70f9596ceb2bbd16e009e8https://doi.org/10.1182/blood-2016-09-738385
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD2015 · 174 citations
  2. 2The addition of sirolimus to the graft‐versus‐host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial2016 · 57 citations
  3. 3The PDL1-PD1 Axis Converts Human T <sub>H</sub> 1 Cells into Regulatory T Cells2011 · 441 citations
  4. 4Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study2016 · 1,021 citations
  5. 5Severe Cytokine-Release Syndrome after T Cell–Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti–IL-6 Therapy Is Safe and Well Tolerated2016 · 169 citations